Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on the treatment of immune dysregulation [3] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] - Avalo has two additional drug candidates: quisovalimab (anti-LIGHT monoclonal antibody) and AVTX-008 (BTLA agonist fusion protein) [3] Product Details - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity [4] - IL-1β is a central driver in the inflammatory process and is implicated in many autoimmune and inflammatory diseases [4] - Evidence suggests that inhibition of IL-1β could be effective in treating conditions such as hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [4] Upcoming Events - Management will participate in the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 3:10 pm ET [2] - The company will also engage in 1x1 and small group meetings at the Leerink Partners Global Healthcare Conference in Miami on March 12, 2025 [2] - Live webcasts and replays of these events will be available on the Avalo Therapeutics website [2]
Avalo Therapeutics to Participate in Upcoming Investor Conferences